Unknown

Dataset Information

0

Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines.


ABSTRACT: Among the well-established alterations contributing to prostate cancer (PCa) pathogenesis, epigenetics is an important player in its development and aggressive disease state. Moreover, since no curative therapies are available for advanced stage disease, there is an urgent need for novel therapeutic strategies targeting this subset of patients. Thus, we aimed to evaluate the combined antineoplastic effects of DNA methylation inhibitor hydralazine and histone deacetylase inhibitors panobinostat and valproic acid in several prostate cell lines. The effect of these drugs was assessed in four PCa (LNCaP, 22Rv1, DU145 and PC-3) cell lines, as well as in non-malignant epithelial (RWPE-1) and stromal (WPMY-1) cell lines, using several assays to evaluate cell viability, apoptosis, proliferation, DNA damage and clonogenic potential. We found that exposure to each epidrug separately reduced viability of all PCa cells in a dose-dependent manner and that combined treatments led to synergic growth inhibitory effects, impacting also on colony formation, invasion, apoptotic and proliferation rates. Interestingly, antitumoral effects of combined treatment were particularly expressive in DU145 cells. We concluded that hydralazine and panobinostat attenuate malignant properties of PCa cells, constituting a potential therapeutic tool to counteract PCa progression.

SUBMITTER: Pacheco MB 

PROVIDER: S-EPMC8308508 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4171604 | biostudies-literature
| S-EPMC8391120 | biostudies-literature
| S-EPMC7718243 | biostudies-literature
| S-ECPF-GEOD-40099 | biostudies-other
| S-EPMC1408081 | biostudies-literature
| S-EPMC4133139 | biostudies-literature
| S-EPMC5504803 | biostudies-literature
| S-EPMC3561759 | biostudies-literature
| S-EPMC5045370 | biostudies-literature
| S-EPMC3182144 | biostudies-literature